IMD-0354 Targets Breast Cancer Stem Cells: A Novel Approach for an Adjuvant to Chemotherapy to Prevent Multidrug Resistance in a Murine Model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Gomez Cabrero, Azucena ^a   Wrasidlo, Wolfgang ^b   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; DOXORUBICIN; I KAPPA B; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CELL POPULATION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CHEMORADIOTHERAPY, ADJUVANT; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS;

EID: 84883137533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073607     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
2. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52: 1213-1225. doi:10.1016/j.yjmcc.2012.03.006. PubMed: 22465037.
3. Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, et al. (2011) Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori 97: 690-692. PubMed: 22322832.
4. Ailles LE, Weissman IL, (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466. doi:10.1016/j.copbio.2007.10.007. PubMed: 18023337.
5. Dean M, (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9. doi:10.1007/s10911-009-9109-9. PubMed: 19224345.
6. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, et al. (2013) Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27: 13-24. doi:10.1096/fj.12-218222. PubMed: 23024375.
7. Baccelli I, Trumpp A, (2012) The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293. doi:10.1083/jcb.201202014. PubMed: 22869594.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. doi:10.1073/pnas.0530291100. PubMed: 12629218.
9. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. doi:10.1101/gad.1061803. PubMed: 12756227.
10. Vinogradov S, Wei X, (2012) Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7: 597-615. doi:10.2217/nnm.12.22. PubMed: 22471722.
11. Nagler C, Zänker KS, Dittmar T, (2011) Cell Fusion, Drug Resistance and Recurrence CSCs. Adv Exp Med Biol 714: 173-182. PubMed: 21506014.
12. Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, et al. (2013) Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 33: 747-754. PubMed: 23482741.
13. Fillmore CM, Kuperwasser C, (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25. doi:10.1186/bcr2023. PubMed: 18366788.
14. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, et al. (2009) Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLOS ONE 4: e8377. doi:10.1371/journal.pone.0008377. PubMed: 20027313.
15. Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, et al. (2004) Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 63: 51-59. doi:10.1016/j.cardiores.2004.03.002. PubMed: 15194461.
16. Tanaka A, Konno M, Muto S, Kambe N, Morii E, et al. (2005) A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324-2331. doi:10.1182/blood-2004-08-3247. PubMed: 15561889.
17. Ling J, Kumar R, (2012) Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett 322: 119-126. doi:10.1016/j.canlet.2012.02.033. PubMed: 22433713.
18. Berenson JR, Ma HM, Vescio R, (2001) The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28: 626-633. doi:10.1053/sonc.2001.29542. PubMed: 11740821.
19. Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, et al. (2011) Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine 7: 665-673. doi:10.1016/j.nano.2011.03.001. PubMed: 21419870.
20. Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, et al. (2011) Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine 7: 665-673.
21. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70. doi:10.1016/S0092-8674(00)81683-9. PubMed: 10647931.
22. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, et al. (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132-2141. doi:10.1172/JCI27648. PubMed: 16862213.
23. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013. PubMed: 21376230.
24. Giaccia AJ, Simon MC, Johnson R, (2004) The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 18: 2183-2194. doi:10.1101/gad.1243304. PubMed: 15371333.
25. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. doi:10.1038/nri1181. PubMed: 13130303.
26. Sutherland RM, (1998) Tumor hypoxia and gene expression--implications for malignant progression and therapy. Acta Oncol 37: 567-574. doi:10.1080/028418698430278. PubMed: 9860315.
27. Sullivan R, Graham CH, (2007) Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26: 319-331. doi:10.1007/s10555-007-9062-2. PubMed: 17458507.
28. Gawenda J, Traub F, Lück HJ, Kreipe H, von Wasielewski R, (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 102: 1-6. doi:10.1007/s10549-006-9311-z. PubMed: 17028987.
29. Wang L, Chen S, Zhang M, Li N, Chen Y, et al. (2012) Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem 113: 2679-2686. doi:10.1002/jcb.24143. PubMed: 22441772.
30. Ohno Y, Nakashima J, Izumi M, Ohori M, Hashimoto T, et al. (2013) Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness. World J Urol, 31: 359-64. PubMed: 23124822.
31. Bajjuri KM, Liu Y, Liu C, Sinha SC, (2011) The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. Chemmedchem 6: 54-59. doi:10.1002/cmdc.201000478. PubMed: 21154805.
32. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405. PubMed: 1540948.
33. Lorger M, Felding-Habermann B, (2010) Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 176: 2958-2971. doi:10.2353/ajpath.2010.090838. PubMed: 20382702.
34. Sambrook J, (2001) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press. 2344pp.
35. Dignam JD, Lebovitz RM, Roeder RG, (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489. doi:10.1093/nar/11.5.1475. PubMed: 6828386.
36. Gomez-Cabrero A, Comes N, Gonzalez-Linares J, de Lapuente J, Borras M, et al. (2005) Use of transduction proteins to target trabecular meshwork cells: outflow modulation by profilin I. Mol Vis 11: 1071-1082. PubMed: 16357826.
37. Ekici OD, Götz MG, James KE, Li ZZ, Rukamp BJ, et al. (2004) Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J Med Chem 47: 1889-1892. doi:10.1021/jm049938j. PubMed: 15055989.
38. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407. doi:10.1126/science.1070200. PubMed: 12089446.
39. Higuchi M, Robinson DS, Cailleau R, Irie RF, Morton DL, (1980) A serologic study of cultured breast cancer cell lines: lack of antibody response to tumour specific membrane antigens in patients. Clin Exp Immunol 39: 90-96. PubMed: 7389200.
40. Price JE, (1990) The biology of metastatic breast cancer. Cancer 66: 1313-1320 doi:10.1002/1097-0142(19900915)66:14+. PubMed: 2205359.
41. Price JE, Polyzos A, Zhang RD, Daniels LM, (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50: 717-721. PubMed: 2297709.
42. Miller FR, Miller BE, Heppner GH, (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3: 22-31. PubMed: 6677618.
43. Pulaski BA, Ostrand-Rosenberg S, (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58: 1486-1493. PubMed: 9537252.
44. Goodell MA, (2005) Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom Chapter 9: Unit9 18. PubMed: 18770827.
45. Kawanabe N, Murakami K, Takano-Yamamoto T, (2006) The presence of ABCG2-dependent side population cells in human periodontal ligaments. Biochem Biophys Res Commun 344: 1278-1283. doi:10.1016/j.bbrc.2006.03.237. PubMed: 16650829.
46. Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, et al. (2006) Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108: 3906-3912. doi:10.1182/blood-2006-05-024687. PubMed: 16912222.
47. Hiraga T, Ito S, Nakamura H, (2011) Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep 25: 289-296. PubMed: 21109989.
48. Mantovani A, (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10: 369-373. doi:10.2174/156652410791316968. PubMed: 20455855.
49. Sugita A, Ogawa H, Azuma M, Muto S, Honjo A, et al. (2009) Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. Int Arch Allergy Immunol 148: 186-198. doi:10.1159/000161579. PubMed: 18849610.
50. Ochiai T, Saito Y, Saitoh T, Dewan MZ, Shioya A, et al. (2008) Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. J Med Dent Sci 55: 49-59. PubMed: 19845150.
51. Uota S, Zahidunnabi Dewan M, Saitoh Y, Muto S, Itai A, et al. (2012) An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer Sci 103: 100-106. doi:10.1111/j.1349-7006.2011.02110.x. PubMed: 21951590.
52. Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, et al. (2010) Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLOS ONE 5: e13831. doi:10.1371/journal.pone.0013831. PubMed: 21072210.
53. Kim RJ, Nam JS, (2011) OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 27: 147-152.
54. Kim SY, Kang JW, Song X, Kim BK, Yoo YD, et al. (2013) Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25: 961-969. doi:10.1016/j.cellsig.2013.01.007. PubMed: 23333246.
55. Prud'homme GJ, (2012) Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 18: 2838-2849. doi:10.2174/138161212800626120. PubMed: 22390767.
56. Volkova M, Russell R 3rd, (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7: 214-220. PubMed: 22758622.
57. Tanaka A, Muto S, Konno M, Itai A, Matsuda H, (2006) A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res 66: 419-426. doi:10.1158/0008-5472.CAN-05-0741. PubMed: 16397257.
58. Mak KK, Wu AT, Lee WH, Chang TC, Chiou JF, et al. (2013) Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-kappaB/microRNA 448 circuit. Mol Nutr Food Res 57: 1123-1134.